Today, we spend 85 cents of every healthcare dollar managing the symptoms of chronic illnesses over a patient’s lifetime. Gene therapies are potential one-time treatments that offer long-lasting benefits for patients and the healthcare system alike. We must think anew about how they are covered and paid for.
The FDA has prioritized the acceleration of gene and cell therapy approvals and expects to receive over 200 investigational new drug applications (INDs) each year.
The current reimbursement system will not be able to accommodate the influx of approvals, which will adversely impact patient access. To help ensure these transformational therapies can be approved in a timely way and patients can access them when they are available, novel development pathways need to be embraced and new value-based arrangements must be tested.
IGT COMMENTS ON POLICY PROPOSALS